Sai Life Sciences shares jump 9%, multibagger stock rallies 19% in 3 days after Q2 results. Why Jefferies hiked target price

Shares of Sai Life Sciences jumped another 9% on Monday, extending gains to 19% over just three sessions as brokerages remained bullish and hiked target prices following the pharmaceutical research and manufacturing company’s Q2 results.

Sai Life shares had surged 12% on Friday following the Q2 announcement, before a slight dip during the Muhurat Trading session on Sunday. The multibagger stock rebounded on Monday, soaring to a fresh 52-week high of Rs 1,897.30 apiece on NSE.

The company reported a net profit of Rs 98 crore for the July-September quarter of FY27, up 17% from Rs 84 crore in the corresponding quarter last year. The results were announced after market hours on Thursday.

The firm’s revenue from operations grew 23% YoY to Rs Rs 659 crore in Q2 FY27 from Rs 537 crore in Q2 FY26. EBITDA rose 20% YoY to Rs 187 crore from Rs 156 crore in the year-ago quarter. However, the company's PAT margin moderated to 15% from 16% in the corresponding period last year.

Also read | Sai Life Sciences shares rally after Q2 results; net profit rises 17%, revenue up 23%

Why did Jefferies hike target price after Q2 results?

Jefferies maintained its ‘Buy’ call on the shares of Sai Life Sciences but increased its target price to Rs 2,050 apiece from Rs 1,610 apiece. The latest target price implies around 18% upside potential from the stock’s previous closing price of Rs 1,744 apiece.

The international brokerage noted that the company delivered a strong beat to its estimates, driven by healthy growth across both CRO and CDMO. The pipeline continued to progress, with one molecule transitioning to the commercial phase and another entering phase-3.

Sai Life Sciences remains among Jefferies’ most preferred CRDMO names, supported by its strong Big Pharma relationships, integrated CRDMO offering and expanding capabilities in niche technologies. It raised its FY27-29 EPS estimates by 3-19%, driven by higher revenue growth assumptions. It said the target price hike accounts for the superior growth profile of the company.

Also read | Sensex, Nifty end Muhurat Trading session in red for first time in 9 years. Are the bulls losing steam?

Sai Life Sciences share price

Sai Life Sciences shares jumped more than 20% in one week and over 24% in a month. The stock has delivered multibagger returns of nearly 106% in 2026 so far and 112% in one year.

The company has a market capitalisation of more than Rs 39,305 crore.

Disclaimer: This article has been written by Debaroti Adhikary, who is not a SEBI-registered Research Analyst or an Investment Adviser. Debaroti Adhikary and his/her ‘relative(s)’ (as defined under Section 2(77) of the Companies Act, 2013) do not hold any financial interest in the companies mentioned in this article as of the date of publication. The views/recommendations mentioned in this article, wherever applicable, are those of the respective SEBI-registered Research Analyst/brokerage and have been reproduced/reported with due attribution. They should not be construed as the views or recommendations of The Economic Times Digital or the journalist. Readers are advised to consider the original research report and make their investment decisions based on their own assessment. Brokerage disclaimers here.